Seeking Alpha

ACADIA Pharmaceuticals (ACAD) announces Pimavanserin has met its primary and key secondary...

ACADIA Pharmaceuticals (ACAD) announces Pimavanserin has met its primary and key secondary endpoints in its Phase III Parkinson's Psychosis Trial. Shares are halted in premarket trading. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)